Receptos Announces Oral Plenary Presentation of TOUCHSTONE Phase 2 Induction Data at Digestive Disease Week 2015
May 15 2015 - 8:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that induction data from
TOUCHSTONE, the Company's Phase 2 trial of ozanimod in ulcerative
colitis (UC), will be reviewed in an oral plenary presentation at
the Digestive Disease Week (DDW) conference in Washington D.C. DDW
is the largest international gathering of physicians, researchers
and academics in the fields of gastroenterology, hepatology,
endoscopy and gastrointestinal surgery.
The data will be presented by Dr. William Sandborn, Principal
Investigator of the trial, Chief of the Division of
Gastroenterology and Director of the UC San Diego Inflammatory
Bowel Disease Center. Details are as follows:
Sunday, May 17, 2015, 3:27 p.m. Eastern time Session: AGA/ASGE
Joint Presidential Plenary Walter E. Washington Convention Center
801 Mt Vernon Pl NW, Washington D.C.
About Ozanimod
Ozanimod is a novel, oral, once daily, selective sphingosine
1-phosphate 1 and 5 receptor modulator in development for
autoimmune indications including relapsing multiple sclerosis (RMS)
and ulcerative colitis (UC). In a Phase 2 trial in patients with
RMS, ozanimod achieved the primary endpoint of reduction in MRI
brain lesion activity as well as secondary endpoints measuring
effects on other MRI parameters. The overall safety profile of
ozanimod was consistent with the results of prior trials and
continues to demonstrate differentiation against other oral agents
for treatment of RMS. Receptos is now conducting a Phase 3 clinical
development program comprised of two trials: RADIANCE and SUNBEAM,
both of which are randomized, double-blind studies designed to
compare 0.5 mg and 1.0 mg of ozanimod against interferon beta-1a
(Avonex®) in patients with RMS.
Ozanimod is also being studied in inflammatory bowel disease
(IBD). The TOUCHSTONE Phase 2 trial of ozanimod in UC met its
primary endpoint and all secondary endpoints with statistical
significance in patients on the 1.0 mg dose of ozanimod in the
8-week induction and 32-week maintenance periods. The overall
safety and tolerability profile of ozanimod was consistent with the
results of the Phase 2 trial in RMS, and continues to support the
potential for orally administered ozanimod to significantly improve
the treatment paradigm for UC patients. Receptos plans to initiate
a Phase 3 program in UC and a Phase 2 program in Crohn's disease in
2015.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, ozanimod, is a sphingosine 1-phosphate 1
and 5 receptor small molecule modulator in development for immune
indications including RMS and IBD. Patents supporting ozanimod were
exclusively licensed to Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046, an
anti-interleukin-13 (IL-13) antibody for eosinophilic esophagitis
(EoE), an allergic/immune-mediated orphan disease, as well as
pipeline, pre-clinical stage assets.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Sep 2024 to Oct 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Oct 2023 to Oct 2024